Angela Cho1, Jeong-Yeol Park2, Shin-Wha Lee3, Dae-Yeon Kim3, Dae-Shik Suh3, Jong-Hyeok Kim3, Yong-Man Kim3, Young-Tak Kim3. 1. Department of Obstetrics and Gynecology, University of Ulsan College of Medicine, Ulsan University Hospital, 881, Bangeojinsunhwando-ro, Dong-gu, Ulsan, 44033, Republic of Korea. 2. Department of Obstetrics and Gynecology, University of Ulsan College of Medicine, Asan Medical Center, 88 Olympic-ro, 43-gil, Songpa-gu, Seoul, 05505, Republic of Korea. catgut1-0@hanmail.net. 3. Department of Obstetrics and Gynecology, University of Ulsan College of Medicine, Asan Medical Center, 88 Olympic-ro, 43-gil, Songpa-gu, Seoul, 05505, Republic of Korea.
Abstract
PURPOSE: The primary objective of our study was to investigate the effectiveness and safety of olaparib maintenance therapy in patients with BRCA-mutated recurrent ovarian cancer in daily practice. The secondary objective of this study was to identify prognostic factors associated with prolonged progression-free survival (PFS) in such patients. METHODS: We conducted a retrospective analysis of 40 patients who received olaparib maintenance treatment. Data on clinicopathological factors, oncological outcomes, and adverse events were obtained from medical records and analyzed. RESULTS: All patients had high-grade serous recurrent ovarian cancer with BRCA mutation and achieved complete or partial response to the most recent platinum-based chemotherapy. After a median follow-up of 14.3 months, the median PFS was 23.7 months (95% confidence interval, 14.1-33.4); however, the median overall survival was not reached. In the log-rank test, the PFS was significantly longer for patients with most recent platinum-free interval (PFI) ≥ 12 months, complete response to the last platinum-based chemotherapy, and less than three lines of previous chemotherapy (p = 0.005, p = 0.016, and p = 0.023, respectively). Most hematologic and non-hematologic adverse events were of grade 1 or 2, and the common adverse events were mostly related to myelosuppression. CONCLUSION: Olaparib maintenance treatment in BRCA-mutated recurrent ovarian cancer is effective and safe in clinical practice. Most recent PFI, response to the last platinum-based chemotherapy, and the number of previous chemotherapy lines were associated with PFS in patients with BRCA-mutated recurrent ovarian cancer.
PURPOSE: The primary objective of our study was to investigate the effectiveness and safety of olaparib maintenance therapy in patients with BRCA-mutated recurrent ovarian cancer in daily practice. The secondary objective of this study was to identify prognostic factors associated with prolonged progression-free survival (PFS) in such patients. METHODS: We conducted a retrospective analysis of 40 patients who received olaparib maintenance treatment. Data on clinicopathological factors, oncological outcomes, and adverse events were obtained from medical records and analyzed. RESULTS: All patients had high-grade serous recurrent ovarian cancer with BRCA mutation and achieved complete or partial response to the most recent platinum-based chemotherapy. After a median follow-up of 14.3 months, the median PFS was 23.7 months (95% confidence interval, 14.1-33.4); however, the median overall survival was not reached. In the log-rank test, the PFS was significantly longer for patients with most recent platinum-free interval (PFI) ≥ 12 months, complete response to the last platinum-based chemotherapy, and less than three lines of previous chemotherapy (p = 0.005, p = 0.016, and p = 0.023, respectively). Most hematologic and non-hematologic adverse events were of grade 1 or 2, and the common adverse events were mostly related to myelosuppression. CONCLUSION:Olaparib maintenance treatment in BRCA-mutated recurrent ovarian cancer is effective and safe in clinical practice. Most recent PFI, response to the last platinum-based chemotherapy, and the number of previous chemotherapy lines were associated with PFS in patients with BRCA-mutated recurrent ovarian cancer.
Entities:
Keywords:
BRCA mutation; Maintenance therapy; Olaparib; Ovarian cancer
Authors: A S Laganà; F Colonese; E Colonese; V Sofo; F M Salmeri; R Granese; B Chiofalo; L Ciancimino; O Triolo Journal: Eur J Gynaecol Oncol Date: 2015 Impact factor: 0.196
Authors: Timothy J Perren; Ann Marie Swart; Jacobus Pfisterer; Jonathan A Ledermann; Eric Pujade-Lauraine; Gunnar Kristensen; Mark S Carey; Philip Beale; Andrés Cervantes; Christian Kurzeder; Andreas du Bois; Jalid Sehouli; Rainer Kimmig; Anne Stähle; Fiona Collinson; Sharadah Essapen; Charlie Gourley; Alain Lortholary; Frédéric Selle; Mansoor R Mirza; Arto Leminen; Marie Plante; Dan Stark; Wendi Qian; Mahesh K B Parmar; Amit M Oza Journal: N Engl J Med Date: 2011-12-29 Impact factor: 91.245
Authors: Robert A Burger; Mark F Brady; Michael A Bookman; Gini F Fleming; Bradley J Monk; Helen Huang; Robert S Mannel; Howard D Homesley; Jeffrey Fowler; Benjamin E Greer; Matthew Boente; Michael J Birrer; Sharon X Liang Journal: N Engl J Med Date: 2011-12-29 Impact factor: 91.245
Authors: L C Hanker; S Loibl; N Burchardi; J Pfisterer; W Meier; E Pujade-Lauraine; I Ray-Coquard; J Sehouli; P Harter; A du Bois Journal: Ann Oncol Date: 2012-08-21 Impact factor: 32.976
Authors: Sabino De Placido; Giovanni Scambia; Giovanni Di Vagno; Emanuele Naglieri; Alessandra Vernaglia Lombardi; Rosalbino Biamonte; Marco Marinaccio; Giacomo Cartenì; Luigi Manzione; Antonio Febbraro; Andrea De Matteis; Gianpietro Gasparini; Maria Rosaria Valerio; Saverio Danese; Francesco Perrone; Rossella Lauria; Michele De Laurentiis; Stefano Greggi; Ciro Gallo; Sandro Pignata Journal: J Clin Oncol Date: 2004-07-01 Impact factor: 44.544
Authors: Maurie Markman; P Y Liu; Sharon Wilczynski; Bradley Monk; Larry J Copeland; Ronald D Alvarez; Caroline Jiang; David Alberts Journal: J Clin Oncol Date: 2003-07-01 Impact factor: 44.544